Hernandez R, Teruel T, Lorenzo M
Department of Biochemistry and Molecular Biology II, Faculty of Pharmacy, Complutense University, Madrid, Spain.
Diabetologia. 2003 Dec;46(12):1618-28. doi: 10.1007/s00125-003-1236-z. Epub 2003 Nov 1.
AIMS/HYPOTHESIS: Rosiglitazone is used to treat Type 2 diabetes because it improves insulin sensitivity. However, the specific molecular mechanism by which this compound acts has not yet been explained.
We used fetal rat primary brown adipocytes cultured for 24 h with or without 10 micro mol/l rosiglitazone and further stimulated for 5 min with 10 nmol/l insulin. Next we measured glucose uptake and GLUT4 translocation and submitted the cells to lysis, immunoprecipitation and immunoblotting in order to measure the insulin signalling cascade.
Rosiglitazone noticeably activated basal glucose uptake in a manner dependent on p38-mitogen-activated protein kinase. Rosiglitazone also produced a 40% increase in insulin-stimulated glucose uptake as a result of increased GLUT4 translocation to the plasma membrane. This happened without changes in the expression of GLUT4 at the mRNA or protein level. This effect correlated with the potentiation by rosiglitazone of insulin-stimulated Tyr phosphorylation of insulin receptor substrate-1 and to a greater extent of insulin receptor substrate-2. It also correlated with the subsequent activation of phosphatidylinositol 3-kinase and Akt, without changes in protein kinase Czeta activity. Rosiglitazone treatment increased insulin receptor expression and insulin-stimulated Tyr phosphorylation of insulin receptor beta-chain, but decreased insulin-stimulated Ser phosphorylation. It also potentiated insulin-induced Tyr phosphorylation of insulin receptor beta-chain and protein tyrosine phosphatase 1B in co-immunoprecipitates and impaired insulin activation of protein tyrosine phosphatase 1B activity.
CONCLUSIONS/INTERPRETATION: At the insulin receptor level, rosiglitazone-induced improvements of insulin sensitivity result from two convergent mechanisms: increased insulin receptor expression and insulin receptor activation.
目的/假设:罗格列酮用于治疗2型糖尿病,因为它能提高胰岛素敏感性。然而,该化合物发挥作用的具体分子机制尚未得到解释。
我们使用原代培养24小时的胎鼠棕色脂肪细胞,分别用或不用10微摩尔/升罗格列酮处理,再用10纳摩尔/升胰岛素进一步刺激5分钟。接下来,我们测量葡萄糖摄取和GLUT4转位,并对细胞进行裂解、免疫沉淀和免疫印迹,以检测胰岛素信号级联反应。
罗格列酮以依赖p38丝裂原活化蛋白激酶的方式显著激活基础葡萄糖摄取。由于GLUT4向质膜转位增加,罗格列酮还使胰岛素刺激的葡萄糖摄取增加了40%。这一过程中GLUT4的mRNA或蛋白质水平表达没有变化。这种作用与罗格列酮增强胰岛素刺激的胰岛素受体底物-1的酪氨酸磷酸化有关,在更大程度上与胰岛素受体底物-2有关。它还与随后磷脂酰肌醇3激酶和Akt的激活有关,而蛋白激酶Czeta活性没有变化。罗格列酮处理增加了胰岛素受体表达以及胰岛素刺激的胰岛素受体β链酪氨酸磷酸化,但降低了胰岛素刺激的丝氨酸磷酸化。它还增强了胰岛素诱导的胰岛素受体β链和蛋白酪氨酸磷酸酶1B在共免疫沉淀中的酪氨酸磷酸化,并削弱了胰岛素对蛋白酪氨酸磷酸酶1B活性的激活。
结论/解读:在胰岛素受体水平,罗格列酮诱导的胰岛素敏感性改善源于两种共同作用机制:胰岛素受体表达增加和胰岛素受体激活。